Iterum Therapeutics ITRM is set to give its latest quarterly earnings report on Thursday, 2024-11-14. Here's what investors need to know before the announcement.
Analysts estimate that Iterum Therapeutics will report an earnings per share (EPS) of $-0.20.
Iterum Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Past Earnings Performance
During the last quarter, the company reported an EPS beat by $0.22, leading to a 0.83% increase in the share price on the subsequent day.
Here's a look at Iterum Therapeutics's past performance and the resulting price change:
| Quarter | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| EPS Estimate | -0.45 | -0.72 | -0.93 | -0.91 |
| EPS Actual | -0.23 | -0.38 | -0.81 | -1.20 |
| Price Change % | 1.0% | -1.0% | -3.0% | 11.0% |
Performance of Iterum Therapeutics Shares
Shares of Iterum Therapeutics were trading at $1.48 as of November 12. Over the last 52-week period, shares are up 30.43%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.
To track all earnings releases for Iterum Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
